Low-dose interleukin-2 treatment increases the proportion of regulatory T cells in patients with rheumatic diseases: A meta-analysis |
| |
| Institution: | 1. Department of Rheumatology, The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China;2. Shanxi Key Laboratory of Immunomicroecology, Taiyuan, Shanxi, China;3. College of Basic Medicine, Shanxi Medical University, Taiyuan, Shanxi, China;4. Pathology, Joint Program in Transfusion Medicine, Brigham and Women’ Hospital/Children''s Hospital, Harvard Medical School, Boston, MA, USA;1. Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, Anhui, China;2. Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Hefei, Anhui, China;3. Department of Cardiovascular Surgery, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China;1. Private Academic Consultant, Bangkok, Thailand;2. University Centre for Research & Development Department of Pharmaceutical Sciences, Chandigarh University Gharuan, Mohali, Punjab, India;1. Department of Internal Medicine, Martinique University Hospital, Fort-de-France, Martinique, France;2. EpiCliV Research Unit, University of French West Indies, Fort-de-France, Martinique, France;3. Department of Internal Medicine, Nîmes University Hospital, France;4. Institute for Regenerative Medicine and Biotherapy, INSERM U1183, Montpellier, France;5. Department of Rheumatology, Martinique University Hospital, France;7. Montpellier-1 University, Faculty of Medicine, France;8. Department of Internal Medicine and Multi-Organic Diseases, Montpelier University Hospital, France;9. Department of Dermatology, Montpellier University Hospital, France;1. Department of Critical Care Medicine, Shengjing Hospital of China Medical University, Shenyang 110004, Liaoning Province, PR China;2. Department of Gastroenterology, Shengjing Hospital of China Medical University, Shenyang 110004, Liaoning Province, PR China;3. Department of Pediatrics, Central Michigan University, Detroit, MI 48201, USA;4. Division of Rheumatology/Allergy and Clinical Immunology, School of Medicine, University of California, Davis, CA 95616, USA;1. Department of Emergency Medicine, Azienda Ospedaliero-Universitaria Pisana, Italy;2. University of Milan, Milan, Italy;3. Department of Clinical and Experimental Medicine, University of Pisa, Italy;4. Department of Surgical, Medical and Molecular Pathology and of Critical Area, University of Pisa, Italy;5. Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Italy;1. Service de Médecine Interne, Centre de Référence Maladies Autoimmunes Systémiques Rares d''Ile de France, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), France;2. APHP-CUP, Hôpital Cochin, Université de Paris, F-75014 Paris, France |
| |
| Abstract: | BackgroundIt is now accepted that immune tolerance disorders caused by inadequate Treg cell function or number are important factors in the development and progression of rheumatic diseases. There is increasing evidence that ld IL-2 treatment increases the proportion of Treg cells in patients' peripheral blood, but this conclusion is still controversial. Here, we performed a meta-analysis of reports documenting the proportion of Treg cells and the rate of adverse events in patients with rheumatic disease before and after the administration of ld IL-2 to better understand its effect and safety on Treg cells in the field of rheumatic diseases.MethodsWe systematically searched PubMed, Embase, Scopus, Cochrane Library, and Web of science databases up to 15th November 2022 and identified studies that reported the proportion of peripheral blood Treg cells before and after ld IL-2 treatment in patients with rheumatic disease. Random-effects model was used to perform a meta-analysis of Treg cell proportions before and after ld IL-2 administration, and a meta-regression analysis was performed to explore heterogeneity. Inconsistency was evaluated using the I-squared index (I2), and publication bias was assessed by examining funnel plot asymmetry using the Egger tests.ResultsEighteen studies involving 1608 patients were included in the meta-analysis. The proportion of Treg cells in peripheral blood of these patients increased significantly after receiving ld IL-2 treatment 1.07 (95% CI 0.86,1.27), p < 0.001, I2 = 67.3%]. Next, Meta-regression was performed for 5 variables including publish year, disease type, trail type and dosage and duration of the medication. The results suggest that these variables do not lead to high heterogeneity. (p = 0.698, 0.267, 0.502, 0.843, 0.560, respectively). And finally, statistical analysis showed no difference in adverse reactions between ld IL-2 group and control group in treatment 1.06 (95% CI 0.86,1.31), p = 0.586, I2 = 53.8%], which is unreliable because the data is so small.ConclusionsLd IL-2 does increase the proportion of peripheral blood Treg cells in patients with rheumatism, and single and cumulative doses must be considered when using ld IL-2. In addition, more studies on the safety of ld IL-2 are urgently needed. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
